We further validated that the acquired resistance to crizotinib, the first generation of the ALK inhibitor, alters the transcriptional patterns of MPE-derived NSCLC cell lines harboring EML4-ALK fusion gene. This evidence concerns the gene EML4 and non-small cell lung carcinoma.